BioWorld

April 5, 2002

View Archived Issues

CancerVax’s Second Round Raises $55M For Canvaxin

CancerVax Corp., a young company studying a vaccine for melanoma and colon cancer, on Monday said it raised $55 million in its second round of financing through the private placement of preferred stock. (BioWorld Today) Read More

LifeTime Acquires Cancer Product From Dovetail For Equity Position

Read More

Rice, First Grain Ever Sequenced, Provides Ideal Biotech Research Model For Improving Multi-Cereals

Read More

GenPhar Reveals Platform, Has Partnerships With Army, NIH

Read More

Other News To Note

Read More